Eli Lilly and Company stock price, LLY

Eli Lilly and Company stock chart:



Eli Lilly and Company close price: 80.19

Stock price forecast:

UP TO +0.01%
Target: 80.20

Total forecasts: 90
Reached: 11 (12.22%)

Total Win: 11.72 (14.28%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%
No results found.

Showing 1-10 of 584 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date
2017-07-2480.1980.180000-00-00
2017-07-2380.1980.460000-00-00
2017-07-2280.1980.420000-00-00
2017-07-2180.1980.440000-00-00
2017-07-2080.1980.20000-00-00
2017-07-1980.1980.210000-00-00
2017-07-1880.1980.030000-00-00
2017-07-1780.1980.080000-00-00
2017-07-1680.1980.260000-00-00
2017-07-1580.1980.260000-00-00

Eli Lilly and Company latest news:


  • 07/12/2017 08:29:48

    Eli Lilly settlement will result in Cialis patent expiring as early as 2018, rather than 2020

    Eli Lilly & Co. said on Wednesday that as part of a settlement with generic companies over its Cialis patent, the exclusive patent is now expected to end on September 27, 2018 at the earliest, roughly a year-and-a-half earlier than the patent was going to expire. The settlement won't affect 2017 financial guidance or mid-term expectations through the rest of the decade, the company said. The dispute centered around a patent on the unit dose of the drug. Eli Lilly defended the disputed patent as "valid" but said that "this is a royalty-bearing license agreement that provides us with more certainty regarding our U.S. exclusivity," according to Michael Harrington, the company's senior vice president and general counsel. Cialis treats erectile dysfunction, but the drug -- tadalfil -- is also sold under the name Adcirca for pulmonary arterial hypertension. Adcirca's patent is still expected to expire on November 21, 2017 or, if the Food and Drug Administration grants the company pediatric exclusivity, on May 21, 2018, Eli Lilly said. Eli Lilly shares rose 1.8% to $83.80 in morning trade. Shares have dropped 2.9% over the last three months, compared with a 4.2% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 05/31/2017 05:15:00

    Eli Lilly's late-stage bladder cancer drug met primary endpoint but will wait for mid-2018 results

    Eli Lilly & Co. said premarket Wednesday that its urothelial carcinoma drug met the primary endpoint in a phase 3 clinical trial. The drug, Cyramza, showed a statistically significant improvement in progression-free survival, Eli Lilly said, but the company expects data on overall survival -- expected in mid-2018 -- will be needed for global regulatory submissions. Urothelial carcinoma involves the urothelial cells that line parts of the urinary tract, though the majority of cases are bladder cancer. Urothelial carcinoma is the ninth most common cancer globally and is typically an aggressive disease, Eli Lilly said. Eli Lilly's late-stage clinical trial enrolled 531 patients globally. Company shares were not active in premarket trade. Shares have declined 5.4% over the last three months, compared with a 2.1% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 05/31/2017 05:12:18

    Eli Lilly's late-stage bladder cancer drug met primary endpoint but will wait is for mid-2018 results

    Eli Lilly & Co. said premarket Wednesday that its urothelial carcinoma drug met the primary endpoint in a phase 3 clinical trial. The drug, Cyramza, showed a statistically significant improvement in progression-free survival, Eli Lilly said, but the company expects data on overall survival -- expected in mid-2018 -- will be needed for global regulatory submissions. Urothelial carcinoma involves the urothelial cells that line parts of the urinary tract, though the majority of cases are bladder cancer. Urothelial carcinoma is the ninth most common cancer globally and is typically an aggressive disease, Eli Lilly said. Eli Lilly's late-stage clinical trial enrolled 531 patients globally. Company shares were not active in premarket trade. Shares have declined 5.4% over the last three months, compared with a 2.1% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 05/12/2017 05:35:55

    UPDATE: Eli Lilly reports positive results in trial of migraine treatment

    Shares of Eli Lilly and Co. jumped 1.6% in premarket trade Friday, after the company said a late-stage study of a migraine treatment met its primary goals. The trial of galcanezumab, an investigational treatment for the prevention of episodic and chronic migraine, met its primary endpoint. "The robust results from these three studies bring us one step closer to helping people experience more migraine-free days, an important treatment goal for those living with this serious disease," Christi Shaw, president of Lilly Bio-Medicines, said in a statement. The company is now planning to submit a biologics license application to the U.S. Food and Drug Administration in the second half. More than 38 million Americans suffer from migraine, which affects three times more women than men. Lilly shares have gained 9% in 2017 through Thursday, while the S&P 500 has gained 7%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 05/12/2017 05:00:34

    Eli Lilly reports positive results in trial of migraine treatment

    Eli Lilly and Co. said Friday a late-stage study of a migraine treatment met its primary goals. The trial of galcanezumab, an investigational treatment for the prevention of episodic and chronic migraine, met its primary endpoint. "The robust results from these three studies bring us one step closer to helping people experience more migraine-free days, an important treatment goal for those living with this serious disease," Christi Shaw, president of Lilly Bio-Medicines, said in a statement. The company is now planning to submit a biologics license application to the U.S. Food and Drug Administration in the second half. More than 38 million Americans suffer from migraine, which affects three times more women than men. Lilly shares were indicating higher in premarket trade, and are up 9% in 2017, while the S&P 500 has gained 7%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 05/01/2017 10:15:34

    Eli Lilly says it has received civil investigative demands about insulin pricing from two state attorney generals

    Eli Lilly & Co. has received civil investigative demands related to its insulin prices from the attorney generals in Washington State and New Mexico, according to a 10-Q financial filing. The Washington State AG's office demand has to do with insulin prices as well as "our relationships with pharmacy benefit managers," industry middlemen that negotiate drug prices, while the demand from the New Mexico AG's office asked about insulin pricing, according to the 10-Q. Eli Lilly is cooperating with both investigations, it said. Insulin prices have skyrocketed over the last several years, making it challenging for diabetics to afford the medication. Eli Lilly, a major insulin manufacturer, has benefited from the industry-wide trend. Eli Lilly shares slumped 0.1% at $81.98 in midday trade on Monday. Shares have risen 5.6% over the last three months, compared with a 4.9% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 04/27/2017 07:05:23

    Top Analyst Upgrades and Downgrades: Amex, Cisco, Eli Lilly, First Solar, McDonald’s, Microsoft, US Steel and More


  • 04/25/2017 10:33:17

    UPDATE 3-Lilly gives no time frame on arthritis drug delay; shares fall

    April 25 (Reuters) - Eli Lilly and Co on Tuesday provided no new information on how long U.S. regulators might delay approval of its closely watched rheumatoid arthritis drug after its surprise rejection by the Food and Drug Administration this month.

  • More trends:

    Ellie MaeELLI | Ellington Financial LLCEFC | Ellington Residential Mortgage REITEARN | Embotelladora Andina S.A.AKO.A | Embotelladora Andina S.A.AKO.B | Embraer-Empresa Brasileira de AeronauticaERJ | EMC CorporationEMC | EMCOR GroupEME | Emerge Energy Services LPEMES | Emergent BiosolutionsEBS |